Related Experiment Video

Updated: May 17, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Combination therapy targeting the Chk1 and Wee1 kinases shows therapeutic efficacy in neuroblastoma

Mike R Russell1, Kirill Levin, JulieAnn Rader

  • 1Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA.

Cancer Research
|November 9, 2012
PubMed

Insights

Neuroblastoma cancer cells show sensitivity to targeting the mitotic regulator Wee1. Inhibiting Wee1, alone or with Chk1 inhibitors, effectively reduces neuroblastoma tumor growth.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Neuroblastoma exhibits unique sensitivity to Chk1 inhibition.
  • This sensitivity suggests downstream effectors of the DNA damage checkpoint pathway are viable therapeutic targets.

Purpose of the Study:

  • To investigate Wee1 as a therapeutic target in neuroblastoma.
  • To evaluate the efficacy of Wee1 inhibition, alone and in combination with Chk1 inhibition.

Main Methods:

  • Assessed Wee1 expression in neuroblastoma cell lines and patient tumors.
  • Utilized genetic and pharmacologic methods to inhibit Wee1 signaling.
  • Tested the synergistic effects of combined Chk1 and Wee1 inhibition in vitro and in vivo.

Main Results:

  • Wee1 was overexpressed in neuroblastoma.
  • Wee1 inhibition demonstrated significant cytotoxicity in most neuroblastoma cell lines (median IC50 300 nmol/L).
  • Combined Chk1 and Wee1 inhibition showed synergistic effects, surpassing individual treatments.

Conclusions:

  • Neuroblastoma cells rely on Wee1 activity for proliferation.
  • Wee1 inhibition represents a promising therapeutic strategy for neuroblastoma patients.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...